Skip to main content
Signal8
Launch Terminal

Sol-Gel Technologies Ltd. (SLGL)

Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd.

NASDAQ:SLGLHealthcare
-0.45%$68.35
AH$68.35+0.00%vs close
Mkt Cap$223.78M
Float1.52M
O/S3.27M
Vol
$ Vol
RVOL
Inst Own40.4%
SI9.0%
Earnings
Dilution
Sol-Gel Technologies Ltd. logoNASDAQ:SLGL$68.35-0.45%
Phase Distribution
15 lead-sponsored trials·0 active·11 completed
Phase 12
Phase 24
Phase 39
Status Overview
Completed11
Stopped4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

    S5G4T-1, S5G4T-2

    Papulopustular Rosacea

    Enrollment
    361
    Start
    Jun 2018
    Primary Completion
    May 2019
    Completion
    May 2019
    NCT03448939
  • Phase 3
    Completed

    A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

    S5G4T-1, S5G4T-2

    Papulopustular Rosacea

    Enrollment
    372
    Start
    Jun 2018
    Primary Completion
    Jun 2019
    Completion
    Jun 2019
    NCT03564119
  • Phase 3
    Terminated

    A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

    S5G4T-1

    Papulopustular Rosacea

    Enrollment
    547
    Start
    Sep 2018
    Primary Completion
    Nov 2019
    Completion
    Nov 2019
    NCT03564145
  • Phase 3
    Completed

    Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

    Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle

    Basal Cell Nevus Syndrome

    Enrollment
    174
    Start
    Feb 2019
    Primary Completion
    Dec 2020
    Completion
    Dec 2020
    NCT03703310
  • Phase 3
    Completed

    Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream

    5-FU Cream, Efudex®

    Actinic Keratosis (AK)

    Enrollment
    462
    Start
    Dec 2018
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT03727074
  • Phase 3
    Completed

    A Study of S6G5T-3 in the Treatment of Acne Vulgaris

    S6G5T-3, S6G5T-8

    Acne Vulgaris

    Enrollment
    424
    Start
    Dec 2018
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT03761784
  • Phase 3
    Completed

    A Study of S6G5T3 in the Treatment of Acne Vulgaris

    S6G5T-3, S6G5T-8

    Acne Vulgaris

    Enrollment
    434
    Start
    Dec 2018
    Primary Completion
    Oct 2019
    Completion
    Oct 2019
    NCT03761810
  • Phase 3
    Terminated

    Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

    Patidegib Topical Gel, 2%

    Basal Cell Nevus Syndrome

    Enrollment
    108
    Start
    Jun 2020
    Primary Completion
    Jul 2021
    Completion
    Jul 2021
    NCT04308395
  • Phase 3
    Completed

    Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

    Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib

    Gorlin Syndrome

    Enrollment
    113
    Start
    Mar 2024
    Primary Completion
    Aug 2026
    Completion
    Sep 2026
    NCT06050122
  • Phase 2
    Completed

    A Study of DER 45-EV Gel to Treat Rosacea

    DER 45 EV, Vehicle

    Rosacea

    Enrollment
    92
    Start
    Jan 2012
    Primary Completion
    Sep 2012
    Completion
    Jan 2013
    NCT00940992
  • Phase 2
    Completed

    Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris

    S6G5T-3, S6G5T-1

    Acne Vulgaris

    Enrollment
    726
    Start
    May 2016
    Primary Completion
    Oct 2017
    Completion
    Oct 2017
    NCT02661958
  • Phase 2
    Terminated

    Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

    S2G6T-1, S2G6T-2

    Tinea Pedis

    Enrollment
    283
    Start
    Sep 2016
    Primary Completion
    Oct 2017
    Completion
    Oct 2017
    NCT02842021
  • Phase 2
    Terminated

    A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

    Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle

    Recurrent Basal Cell Carcinoma

    Enrollment
    50
    Start
    Dec 2019
    Primary Completion
    Apr 2021
    Completion
    Apr 2021
    NCT04155190
  • Phase 1
    Completed

    MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3

    S6G5T-3, Retin-A® 0.1% Cream

    Acne Vulgaris

    Enrollment
    62
    Start
    Jun 2019
    Primary Completion
    Feb 2020
    Completion
    Feb 2020
    NCT04059523
  • Phase 1
    Completed

    Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

    Encapsulated Benzoyl Peroxide Cream

    Papulopustular Rosacea

    Enrollment
    31
    Start
    Jun 2020
    Primary Completion
    Jul 2021
    Completion
    Jul 2021
    NCT05675501
Search ClinicalTrials.gov for “Sol-Gel Technologies”